Eli Lilly's Mounjaro Reduces Cancer Risk: Analysts Expect Significant Upside for Stock

Eli Lilly's Mounjaro has shown potential in reducing overall cancer risk in recent research. Analyst price targets suggest a significant upside for Eli Lilly's stock, with an average 1-year target of $892.33 and a potential 24.84% increase from its current price. Current brokerage recommendations rate Eli Lilly as "Outperform" with a consensus rating of 2.0.

Eli Lilly's (LLY) Mounjaro, a GLP-1 receptor agonist, has shown promise in reducing overall cancer risk according to recent research. The study, published on Jama Oncology, analyzed electronic health records of over 80,000 obese individuals, revealing a significant reduction in cancer risk among users of GLP-1 medications compared to non-users [2]. However, the study also noted a slight uptick in kidney cancer risk.

Analysts are optimistic about Eli Lilly's stock prospects. The average one-year price target for Eli Lilly and Co (LLY) is $892.33, suggesting a potential 24.84% increase from its current price of $714.78 [1]. Brokerage recommendations also favor Eli Lilly, with a consensus rating of 2.0, indicating an "Outperform" status [1].

Eli Lilly's Mounjaro is not the only GLP-1 drug linked to lower cancer risk. Novo Nordisk's Ozempic, another GLP-1 receptor agonist, has also shown similar findings in the study [2]. The study led by Hao Dai, a health data scientist at Indiana University, suggests that the incidence rate for 14 cancer types stood at 13.6 among GLP-1 users compared to 16.4 among non-users [2].

While the findings are promising, the study calls for a longer-term follow-up to evaluate the clinical implications and reasons behind the findings [2]. The retrospective nature of the study and the fact that no GLP-1 drugs are indicated for cancer underscore the need for further research.

References:
[1] https://www.gurufocus.com/news/3075549/eli-lillys-lly-mounjaro-shows-potential-in-reducing-cancer-risk
[2] https://seekingalpha.com/news/4488383-glp-1-drugs-are-linked-lower-cancer-risk